Pre-made Guselkumab benchmark antibody ( Whole mAb, anti-IL23A/IL23 therapeutic antibody, Anti-IL23P19/P19/SGRF Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Guselkumab biosimilar, Whole mAb, Anti-IL23A/IL23 Antibody: Anti-IL23P19/P19/SGRF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Guselkumab, sold under the brand name Tremfya, is a monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-255-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Guselkumab biosimilar, Whole mAb, Anti-IL23A/IL23 Antibody: Anti-IL23P19/P19/SGRF therapeutic antibody
INN Name	Guselkumab
Target	IL23
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	4m6m:HL/4m6n:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2013
Year Recommended	2014
Companies	Janssen Biotech;MorphoSys;Taiho Pharmaceutical
Conditions Approved	Erythrodermic psoriasis;Palmoplantar pustulosis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis
Conditions Active	Crohn's disease;Hidradenitis suppurativa;Ulcerative colitis;Familial adenomatous polyposis;Psoriasis;Giant cell arteritis;Lupus nephritis;Systemic scleroderma
Conditions Discontinued	Rheumatoid arthritis
Development Tech	MorphoSys HuCAL Phage Display